Business Services Industry

NeoRx and ABC Labs Extend Clinical Manufacturing Agreement

Business Wire, Jan 30, 2001

Business Editors, Health/Medical Writers

SEATTLE--(BUSINESS WIRE)--Jan. 30, 2001

NeoRx Corporation (Nasdaq:NERX) and ABC Laboratories (Columbia, MO) have extended their existing agreement for ABC Laboratories to manufacture NeoRx's STR product for the Phase III clinical trials in multiple myeloma. ABC Laboratories had supplied doses of STR for the Phase I/II clinical trails and will continue to supply the doses needed for Phase III. As previously announced, NeoRx's STR clinical trials are currently on hold, pending FDA review of certain information and receipt of FDA authorization to restart those trials.

"This agreement helps ensure NeoRx its supply of STR for its pending phase III clinical trials to treat patients with multiple myeloma," said Paul G. Abrams, M.D., J.D., Chief Executive Officer, NeoRx Corporation.

"Producing the STR product for NeoRx fits perfectly with ABC Laboratories' strategy in radiopharmaceutical manufacturing and holds promise for cancer patients. Our people are delighted to be involved," said Dr. Jake Halliday, President & CEO of ABC Laboratories.

About NeoRx

NeoRx Corporation develops innovative biopharmaceutical products designed to improve treatments for patients with cancer. In addition to STR for multiple myeloma, NeoRx is conducting a phase I trial of its Pretarget(R) Technology in lymphoma, and currently plans to test STR indications in breast and prostate cancers once clinical hold is lifted. Visit NeoRx at www.neorx.com. To receive NeoRx news releases via email, register at www.neorx.com/news/pr.html.> About ABC Labs

ABC Laboratories is an NRC licensed, FDA registered establishment experienced in research, development and manufacturing of therapeutic radiopharmaceuticals, diagnostics, and medical devices. ABC has the infrastructure and professionals required for this specialized arena. Visit ABC at www.abclabs.com.

This release contains forward-looking statements relating to the development of the Company's products and future operating results that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect the Company's actual results include the progress, costs and results of clinical trials, the availability, cost and timely delivery of materials and services from third party suppliers and collaborative partners, the satisfaction of regulatory requirements, and the receipt, timing, terms and conditions of required regulatory approvals. Reference is made to the Company's latest Quarterly Report on Form 10 - Q filed with the Securities and Exchange Commission for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. The Company undertakes no obligation to publicly update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

NeoRx is a registered trademark of NeoRx Corporation in the United States and/or foreign countries.